Cargando…

Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity

Detalles Bibliográficos
Autores principales:	Huang, Po-Lin, Kan, Hung-Tsai, Hsu, Ching-Hsuan, Hsieh, Hsin-Ta, Cheng, Wan-Chien, Huang, Ren-Yeong, You, Jhong-Jhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429065/ https://www.ncbi.nlm.nih.gov/pubmed/37587442 http://dx.doi.org/10.1186/s12967-023-04410-1

Ejemplares similares

A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
por: Huang, Po-Lin, et al.
Publicado: (2023)

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
por: Puigdelloses, Montserrat, et al.
Publicado: (2021)

Correction: CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
Publicado: (2021)

The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer
por: Xu, Naijin, et al.
Publicado: (2019)

An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma
por: Wei, Mulan, et al.
Publicado: (2018)

Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect
por: Oya, Kazumasa, et al.
Publicado: (2021)

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity
por: Feng, Yan, et al.
Publicado: (2022)

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
por: Shi, Ning, et al.
Publicado: (2022)

Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy
por: Chen, Xianhui, et al.
Publicado: (2021)

A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
por: Geuijen, Cecile, et al.
Publicado: (2021)

ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma
por: Zhang, Peng, et al.
Publicado: (2023)

The natural compound gracillin exerts potent antitumor activity by targeting mitochondrial complex II
por: Min, Hye-Young, et al.
Publicado: (2019)

Dataset on Cs-137 in waters surrounding Taiwan
por: Huang, Ting-Hsuan, et al.
Publicado: (2023)

Enhancing the antitumor potency of T cells redirected by bispecific antibodies
por: Chang, Chien-Hsing, et al.
Publicado: (2017)

Potent CD4(+) T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition
por: Deppisch, Nina, et al.
Publicado: (2016)

Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis
por: Chen, Linying, et al.
Publicado: (2019)

Novel Pan-Pim Kinase Inhibitors With Imidazopyridazine and Thiazolidinedione Structure Exert Potent Antitumor Activities
por: Sawaguchi, Yuichi, et al.
Publicado: (2021)

IL-24-Armed Oncolytic Vaccinia Virus Exerts Potent Antitumor Effects via Multiple Pathways in Colorectal Cancer
por: Deng, Lili, et al.
Publicado: (2021)

Systemic delivery of liposome-anchored anti-CD137 and IL2-Fc prevents lethal toxicity and elicits potent antitumor immunity
por: Zhang, Yuan, et al.
Publicado: (2015)

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells
por: Rajendran, Sakthi, et al.
Publicado: (2019)

Pitavastatin Exerts Potent Anti-Inflammatory and Immunomodulatory Effects via the Suppression of AP-1 Signal Transduction in Human T Cells
por: Chen, Liv Weichien, et al.
Publicado: (2019)

Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways
por: Chen, Zuhua, et al.
Publicado: (2017)

CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer
por: Yi, Ling, et al.
Publicado: (2022)

HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
por: Zhang, Jibin, et al.
Publicado: (2020)

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
por: Yano, Hiroshi, et al.
Publicado: (2014)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Chen, Shih-Hsun, et al.
Publicado: (2021)

LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation
por: Sung, Eunsil, et al.
Publicado: (2022)

Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma
por: Liu, Xu-Jie, et al.
Publicado: (2017)

Lipid Nanoparticle Delivery System for mRNA Encoding B7H3‐redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors
por: Huang, Cheng, et al.
Publicado: (2022)

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
por: Hinner, Marlon J, et al.
Publicado: (2015)

Coriloxin Exerts Antitumor Effects in Human Lung Adenocarcinoma Cells
por: Kuo, Yu-Hsuan, et al.
Publicado: (2022)

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity
por: Castoldi, R, et al.
Publicado: (2013)

Cell-type specific potent Wnt signaling blockade by bispecific antibody
por: Lee, Nam-Kyung, et al.
Publicado: (2018)

Pd@Ag Nanosheets in Combination with Amphotericin B Exert a Potent Anti-Cryptococcal Fungicidal Effect
por: Zhang, Chao, et al.
Publicado: (2016)

CD137L-DCs, Potent Immune-Stimulators—History, Characteristics, and Perspectives
por: Zeng, Qun, et al.
Publicado: (2019)

Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities
por: Chen, Yiran, et al.
Publicado: (2020)

IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity
por: Yang, Min, et al.
Publicado: (2021)

MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
por: Li, Hongjian, et al.
Publicado: (2020)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
por: Gao, Jing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vfb4i2j1h6c49nj931s4ilechb